Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes

A. V. Karadonta, M. G. Alexandrakis, Taxiarchis Kourelis, A. Manola, K. Garlemou, N. E. Stathakis, Despina Kyriakou

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Myelodysplastic Syndrome (MDS) cells present genetic instability and dysregulation of the gene C3ORF9, which was isolated from an MDS cDNA library and codes for a putative protein. We studied the expression of C3ORF9 in MDS syndromes to contribute to the understanding of the pathophysiology of MDS. One hundred and thirty-one patients and 35 healthy controls were involved in our study. Bone marrow aspirates and isolated CD34+ cells were used. Gene expression was estimated by quantitative PCR. C3ORF9 was found to be down-regulated in patients with CMML compared to the controls (p<0.01). There was no difference between RARS and the controls (p=0.1), while increased expression was found in RA, RAEB and RAEB-T (p<0.01 for all). No mutations or polymorphism were detected in our population. CD34+ cells expressed higher levels of C3ORF9 (p<0.01) in patients. The gene expression was correlated to the percentage of + cells in RAEB and RAEB-T (r=0.64). The altered C3ORF9 expression was possibly due to different gene regulation in these patients and/or to the increased CD34+ cells.

Original languageEnglish (US)
Pages (from-to)787-793
Number of pages7
JournalInternational Journal of Immunopathology and Pharmacology
Volume22
Issue number3
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Refractory Anemia with Excess of Blasts
Myelodysplastic Syndromes
Gene Expression
Gene Library
Genes
Bone Marrow
Polymerase Chain Reaction
Mutation
Population
Proteins

Keywords

  • C3ORF9
  • Chromosome abnormalities
  • MDS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes. / Karadonta, A. V.; Alexandrakis, M. G.; Kourelis, Taxiarchis; Manola, A.; Garlemou, K.; Stathakis, N. E.; Kyriakou, Despina.

In: International Journal of Immunopathology and Pharmacology, Vol. 22, No. 3, 01.01.2009, p. 787-793.

Research output: Contribution to journalArticle

Karadonta, AV, Alexandrakis, MG, Kourelis, T, Manola, A, Garlemou, K, Stathakis, NE & Kyriakou, D 2009, 'Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes', International Journal of Immunopathology and Pharmacology, vol. 22, no. 3, pp. 787-793. https://doi.org/10.1177/039463200902200325
Karadonta, A. V. ; Alexandrakis, M. G. ; Kourelis, Taxiarchis ; Manola, A. ; Garlemou, K. ; Stathakis, N. E. ; Kyriakou, Despina. / Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes. In: International Journal of Immunopathology and Pharmacology. 2009 ; Vol. 22, No. 3. pp. 787-793.
@article{7f059f35ad574589ac4fbd94bb7590c6,
title = "Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes",
abstract = "Myelodysplastic Syndrome (MDS) cells present genetic instability and dysregulation of the gene C3ORF9, which was isolated from an MDS cDNA library and codes for a putative protein. We studied the expression of C3ORF9 in MDS syndromes to contribute to the understanding of the pathophysiology of MDS. One hundred and thirty-one patients and 35 healthy controls were involved in our study. Bone marrow aspirates and isolated CD34+ cells were used. Gene expression was estimated by quantitative PCR. C3ORF9 was found to be down-regulated in patients with CMML compared to the controls (p<0.01). There was no difference between RARS and the controls (p=0.1), while increased expression was found in RA, RAEB and RAEB-T (p<0.01 for all). No mutations or polymorphism were detected in our population. CD34+ cells expressed higher levels of C3ORF9 (p<0.01) in patients. The gene expression was correlated to the percentage of + cells in RAEB and RAEB-T (r=0.64). The altered C3ORF9 expression was possibly due to different gene regulation in these patients and/or to the increased CD34+ cells.",
keywords = "C3ORF9, Chromosome abnormalities, MDS",
author = "Karadonta, {A. V.} and Alexandrakis, {M. G.} and Taxiarchis Kourelis and A. Manola and K. Garlemou and Stathakis, {N. E.} and Despina Kyriakou",
year = "2009",
month = "1",
day = "1",
doi = "10.1177/039463200902200325",
language = "English (US)",
volume = "22",
pages = "787--793",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "3",

}

TY - JOUR

T1 - Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes

AU - Karadonta, A. V.

AU - Alexandrakis, M. G.

AU - Kourelis, Taxiarchis

AU - Manola, A.

AU - Garlemou, K.

AU - Stathakis, N. E.

AU - Kyriakou, Despina

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Myelodysplastic Syndrome (MDS) cells present genetic instability and dysregulation of the gene C3ORF9, which was isolated from an MDS cDNA library and codes for a putative protein. We studied the expression of C3ORF9 in MDS syndromes to contribute to the understanding of the pathophysiology of MDS. One hundred and thirty-one patients and 35 healthy controls were involved in our study. Bone marrow aspirates and isolated CD34+ cells were used. Gene expression was estimated by quantitative PCR. C3ORF9 was found to be down-regulated in patients with CMML compared to the controls (p<0.01). There was no difference between RARS and the controls (p=0.1), while increased expression was found in RA, RAEB and RAEB-T (p<0.01 for all). No mutations or polymorphism were detected in our population. CD34+ cells expressed higher levels of C3ORF9 (p<0.01) in patients. The gene expression was correlated to the percentage of + cells in RAEB and RAEB-T (r=0.64). The altered C3ORF9 expression was possibly due to different gene regulation in these patients and/or to the increased CD34+ cells.

AB - Myelodysplastic Syndrome (MDS) cells present genetic instability and dysregulation of the gene C3ORF9, which was isolated from an MDS cDNA library and codes for a putative protein. We studied the expression of C3ORF9 in MDS syndromes to contribute to the understanding of the pathophysiology of MDS. One hundred and thirty-one patients and 35 healthy controls were involved in our study. Bone marrow aspirates and isolated CD34+ cells were used. Gene expression was estimated by quantitative PCR. C3ORF9 was found to be down-regulated in patients with CMML compared to the controls (p<0.01). There was no difference between RARS and the controls (p=0.1), while increased expression was found in RA, RAEB and RAEB-T (p<0.01 for all). No mutations or polymorphism were detected in our population. CD34+ cells expressed higher levels of C3ORF9 (p<0.01) in patients. The gene expression was correlated to the percentage of + cells in RAEB and RAEB-T (r=0.64). The altered C3ORF9 expression was possibly due to different gene regulation in these patients and/or to the increased CD34+ cells.

KW - C3ORF9

KW - Chromosome abnormalities

KW - MDS

UR - http://www.scopus.com/inward/record.url?scp=70350542499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350542499&partnerID=8YFLogxK

U2 - 10.1177/039463200902200325

DO - 10.1177/039463200902200325

M3 - Article

C2 - 19822096

AN - SCOPUS:70350542499

VL - 22

SP - 787

EP - 793

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 3

ER -